biostudies-literatureSavid-Frontera CCCR NIH HHSIntramural NIH HHSSecretaria de Ciencia y Tecnología-UNCIntramural Research Program of the Center for Cancer Research, National Cancer InstituteNCI NIH HHSFundación para el Progreso de la Medicina115-133https://www.ebi.ac.uk/biostudies/studies/S-EPMC8739399biostudies-literatureUnknown14(2)<b>Aim:</b> The aim of this work is to utilize a gene expression procedure to safely express systemic IL-12 and evaluate its effects in mouse tumor models<b>. Materials & methods:</b> Secondary lymphoid organs and tumors from EL4 and B16 tumor-bearing mice were analyzed by supervised and unsupervised methods. <b>Results:</b> IL-12 cDNA induced systemic IL-12 protein levels lower than the tolerated dose in patients. Control of tumor growth was observed in subcutaneous B16 and EL4 tumors. Systemic IL-12 expression induced a higher frequency of both total tumor-infiltrated CD45⁺ cells and proliferative IFN-γ⁺CD8⁺ T cells along with a lower frequency of CD4⁺FOXP3⁺ and CD11b⁺Gr-1⁺ cells. <b>Conclusion:</b> This approach characterizes the systemic effects of IL-12, helping to improve treatment of metastases or solid tumors.ImmunotherapySafety levels of systemic IL-12 induced by cDNA expression as a cancer therapeutic.PMC8739399GC N°1HHSN261200800001EHHSN261200800001CZIA BC0092832018-2021ZIA BC 009283Viano MEReynolds DMatellon MBaez NSSavid-Frontera CRodriguez-Galan MCA Young HfalseSafety levels of systemic IL-12 induced by cDNA expression as a cancer therapeutic.<b>Aim:</b> The aim of this work is to utilize a gene expression procedure to safely express systemic IL-12 and evaluate its effects in mouse tumor models<b>. Materials & methods:</b> Secondary lymphoid organs and tumors from EL4 and B16 tumor-bearing mice were analyzed by supervised and unsupervised methods. <b>Results:</b> IL-12 cDNA induced systemic IL-12 protein levels lower than the tolerated dose in patients. Control of tumor growth was observed in subcutaneous B16 and EL4 tumors. Systemic IL-12 expression induced a higher frequency of both total tumor-infiltrated CD45⁺ cells and proliferative IFN-γ⁺CD8⁺ T cells along with a lower frequency of CD4⁺FOXP3⁺ and CD11b⁺Gr-1⁺ cells. <b>Conclusion:</b> This approach characterizes the systemic effects of IL-12, helping to improve treatment of metastases or solid tumors.2022-01-01T00:00:00Z2022 Feb2025-04-05T09:03:11.81Z2025-04-05T09:03:11.81ZS-EPMC87393993478325710.2217/imt-2021-0080